Background: Nivolumab in an anti-PD1 monoclonal antibody that activates the immune system by stimulating T-cell proliferation. Although systemic and cardiac adverse events are described, cardiac toxicity from Nivolumab is rare with poorly understood etiopathogenetic mechanism.
Left ventricular dysfunction in cardiac metastatic melanoma: nivolumab induced immunotoxicity or direct myocardial damage?
G. Citarelli;VG. Lavolpe;M. Sassara;P. Caldarola
2020-01-01
Abstract
Background: Nivolumab in an anti-PD1 monoclonal antibody that activates the immune system by stimulating T-cell proliferation. Although systemic and cardiac adverse events are described, cardiac toxicity from Nivolumab is rare with poorly understood etiopathogenetic mechanism.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
